COMPANY:

RareCyte

"RareCyte, Inc...announced today the completion of a $20M financing from new and existing investors. The funding is expected to enable the Company to drive an expansion of the successful Orion Spatial Biology platform including commercializing new multiplex assays, reagent products, and software applications. The funding is also expected to support expansion of RareCyte's Precision Biology Services including spatial biology and liquid biopsy assays utilizing its Seattle, WA-based labs and scientific personnel performed under CLIA and ISO 13485 certifications. Global commercial expansion in regions outside the US will be amplified by the new funding."

"Navigate BioPharma Services, Inc...announces the launch of its new multiplex spatial biology assay services for rapid, whole-slide imaging and analysis of tissue sections at subcellular resolution. These assays utilize the Orion™ platform from RareCyte, Inc. and feature ready-to-run assay panels, as well as customization to serve studies across multiple drug targets and therapeutic areas."

"SOPHiA GENETICS...announced that RareCyte Inc...is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM™ Platform to complement its Precision Biology Services portfolio...The SOPHiA GENETICS technology will help RareCyte's team of scientists and engineers as they continue to develop next-generation products and services that advance precision medicine and biomedical research."